BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

EXELA HOLDINGS, LLC — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Report

EXELA HOLDINGS, LLC

via BROWN RUDNICK LLP

4th Quarter (Oct 1 - Dec 31) · 2014Posted Jan 20, 2015Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: EXELA HOLDINGS, LLC
Description: pharmaceutical manufacturing
Location: Virginia · United States of America

Registrant

Firm: BROWN RUDNICK LLP
Description: Law Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Pharmacy
Implementation of P.L. 112-144 (FDA Safety and Innovation Act)
LobbyistsHENRY W MENN iii · LISA LAYMAN
Covered position (HENRY W MENN iii): CoS, Sen. Bob Graham (01 - 04)
Covered position (LISA LAYMAN): SPA, Sen. Stabenow (05-07)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.